A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm

To characterize satisfaction with current standard-of-care botulinum neurotoxin type A (BoNT/A) treatment for blepharospasm, we performed a cross-sectional, structured survey in subjects with blepharospasm who had received ≥2 BoNT/A cycles. Subjects were interviewed immediately before re-injection to evaluate treatment satisfaction, time course of treatment effects, preferred injection intervals, Jankovic Rating Scale (JRS), and Blepharospasm Disability Index (BSDI).Subjects’ (n=114) last treatment was onabotulinumtoxinA (n=78), incobotulinumtoxinA (n=35), or abobotulinumtoxinA (n=1).

Source: Journal of the Neurological Sciences - May 15, 2016 Category: Neurology Authors: John Fezza, John Burns, Julie Woodward, Daniel Truong, Thomas Hedges, Amit Verma Tags: Clinical Research Paper Source Type: research